https://orcid.org/0000-0002-7677-2889
References
- Andrianov AM, Nikolaev GI, Kornoushenko YV, Xu W, Jiang S, Tuzikov AV. 2019. In silico identification of novel aromatic compounds as potential HIV-1 entry inhibitors mimicking cellular receptor CD4. Viruses. 11(8):746.
- Barros CS, Cirne-Santos CC, Garrido V, Barcelos I, Stephens PRS, Giongo V, Teixeira VL, Paixão ICNP. 2016. Anti-HIV-1 activity of compounds derived from marine alga Canistrocarpus cervicornis. J Appl Phycol. 28(4):2523–2527.
- Chen Y, Kirchmair J. 2020. Cheminformatics in natural product-based drug discovery. Mol Inf. 39(12):2000171.
- Curreli F, Kwon YD, Zhang H, Scacalossi D, Belov DS, Tikhonov AA, Andreev IA, Altieri A, Kurkin AV, Kwong PD, et al. 2015. Structure-based design of a small molecule CD4-antagonist with broad spectrum anti-HIV-1 activity. J Med Chem. 58(17):6909–6927.
- Food and Drug Administration (FDA). 2020. Silver Spring, MD: FDA. [accessed 2021 May 21]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212950s000lbl.pdf.
- Langley DR, Kimura SR, Sivaprakasam P, Zhou N, Dicker I, McAuliffe B, Wang T, Kadow JF, Meanwell NA, Krystal M. 2015. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins. 83(2):331–350.
- Unites Nations Programme on HIV/AIDS (UNAIDS). 2021. Geneva, Switzerland: UNAIDS. [accessed 2021 July 15]. https://www.unaids.org/en.